Bank of America
SLN

Bank of America’s Silence Therapeutics SLN Stock Holding History

Bank of America’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$157K Buy
29,773
+26,807
+904% +$148K ﹤0.01% 5434
2025
Q4 		$18K Sell
2,966
-565
-16% -$3.62K ﹤0.01% 6072
2025
Q3 		$18.3K Sell
3,531
-1,564
-31% -$8.69K ﹤0.01% 7086
2025
Q2 		$29.6K Sell
5,095
-59,791
-92% -$256K ﹤0.01% 6966
2025
Q1 		$183K Sell
64,886
-434,180
-87% -$2.12M ﹤0.01% 6225
2024
Q4 		$3.43M Buy
499,066
+498,032
+48,166% +$6.43M ﹤0.01% 3955
2024
Q3 		$18.8K Sell
1,034
-8,978
-90% -$167K ﹤0.01% 6757
2024
Q2 		$190K Sell
10,012
-1,980
-17% -$42.1K ﹤0.01% 5908
2024
Q1 		$259K Buy
11,992
+10,916
+1,014% +$237K ﹤0.01% 5749
2023
Q4 		$18.7K Buy
1,076
+526
+96% +$5.91K ﹤0.01% 6801
2023
Q3 		$5.4K Hold
550
– – ﹤0.01% 6978
2023
Q2 		$3.02K Hold
550
– – ﹤0.01% 7080
2023
Q1 		$3.41K Buy
+550
New +$6.49K ﹤0.01% 7138
2022
Q2 		– Sell
-770
Closed -$15K – 8342
2022
Q1 		$15K Buy
+770
New +$15.3K ﹤0.01% 7624

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Bank of America's SLN Position: Q1 2026 in Review

Bank of America increased its Silence Therapeutics (SLN) stake by 904% in Q1 2026, buying an estimated $148K and bringing the position to 29,773 shares worth $157K. The position accounts for ﹤0.01% of the portfolio, ranked #5434.

Bank of America first reported a position in SLN in Q1 2022 and has held it in 14 quarters since. The position peaked at $3.43M in Q4 2024. 56 funds tracked by Wall St. Rank hold SLN as of Q1 2026.

  • Bank of America held 29,773 shares of Silence Therapeutics worth $157K as of Q1 2026.
  • Bank of America bought 26,807 Silence Therapeutics shares in Q1 2026, an estimated $148K.
  • Silence Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #5434 holding.
  • Bank of America first reported a position in Silence Therapeutics in Q1 2022 and has held it in 14 quarters since.
  • Bank of America's Silence Therapeutics position peaked at $3.43M in Q4 2024.
  • 56 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.